{"id":"ffa974a327ff","type":"article","url":"https://hartvaat.nl/2019/08/01/icd-bij-diabetes-met-niet-ischemisch-systolisch-hf-danish-analyse/","title":"ICD bij diabetes met niet-ischemisch systolisch HF: DANISH-analyse","title_en":"The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog"],"tags":[],"journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","doi":"10.1093/europace/euz114","source_url":"https://doi.org/10.1093/europace/euz114","authors":["Rasmus Rørth","Jens Jakob Thune","Jens C Nielsen","Jens Haarbo","Lars Videbæk","Eva Korup","James Signorovitch","Niels E Bruun","Hans Eiskjær","Christian Hassager","Jesper Hastrup Svendsen","Dan E Høfsten","Christian Torp-Pedersen","Steen Pehrson","Lars Køber","Søren L Kristensen"],"significance":6,"published":"2019-08-01","source_date":"2019-08-01","image":"","kennis":[],"congress":"","summary_en":"This DANISH subanalysis examined whether diabetes modifies the ICD benefit in non-ischemic heart failure, finding that diabetic patients do not derive significantly different survival benefit from prophylactic defibrillator therapy.","created":"2026-07-03T10:28:04Z","updated":"2026-07-03T13:27:16Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"DANISH subanalyse naar het effect van ICD bij diabetespatiënten met niet-ischemisch systolisch hartfalen.","abstract_original":"AIMS: Implantable cardioverter-defibrillator (ICD) implantation reduce the risk of sudden cardiac death, but not all-cause death in patients with non-ischaemic systolic heart failure (HF). Whether co-existence of diabetes affects ICD treatment effects is unclear. METHODS AND RESULTS: We examined the effect of ICD implantation on risk of all-cause death, cardiovascular death, and sudden cardiac death (SCD) according to diabetes status at baseline in the Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischaemic Systolic Heart Failure on Mortality (DANISH) trial. Outcomes were analysed by use of cumulative incidence curves and Cox regressions models. Of the 1116 patients enrolled, 211 (19%) had diabetes at baseline. Patients with diabetes were more obese, had worse kidney function and more were in New York Heart Association Class III/IV. The risk of device infections and other complications in the ICD group was similar among patients with and without diabetes (6.1% vs. 4.6% P = 0.54). Irrespective of treatment group, diabetes was associated with higher risk of all-cause death, cardiovascular death, and SCD. The treatment effect of ICD in patients with diabetes vs. patients without diabetes was hazard ratio (HR) = 0.92 (0.57-1.50) vs. HR = 0.85 (0.63-1.13); Pinteraction = 0.60 for all-cause mortality, HR = 0.99 (0.58-1.70) vs. HR = 0.70 (0.48-1.01); Pinteraction = 0.25 for cardiovascular death, and HR = 0.81 (0.35-1.88) vs. HR = 0.40 (0.22-0.76); Pinteraction = 0.16 for sudden cardiac death. CONCLUSION: Among patients with non-ischaemic systolic HF, diabetes was associated with higher incidence of all-cause mortality, primarily driven by cardiovascular mortality including SCD. Treatment effect of ICD therapy was not significantly modified by diabetes which might be due to lack of power."}